QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Erratum An erratum has been published All Versions of this Article: mol.106.027730v1 70/5/1708    most recent Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kaspárková, J. Articles by Brabec, V. Search for Related Content PubMed PubMed Citation Articles by Kaspárková, J. Articles by Brabec, V.

Molecular Aspects of Antitumor Effects of a New Platinum(IV) Drug

Jana Kaspárková, Olga Nováková, Oldich Vrána, Francesco Intini, Giovanni Natile, and Viktor Brabec

Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic (J.K., O.N., O.V., V.B.); and Department of Pharmaceutical Chemistry, University of Bari, Bari, Italy (F.I., G.N.)

The new platinum(IV) complex cis,trans,cis-[PtCl₂(CH₃COO)₂-(NH₃)(1-adamantylamine)] [adamplatin(IV)] seems promising for the perspective application in therapy of corresponding tumors. It is therefore of great interest to understand details of mechanisms underlying its biological efficacy. Cellular uptake of the drug, alterations in the target DNA induced by platinum drugs along with processing of platinum-induced damage to DNA and drug inactivation by sulfur-containing compounds belong to major pharmacological factors affecting antitumor effects of platinum compounds. We examined in the present work the significance of these factors in the mechanism of antitumor effects of adamplatin(IV) and compared the results with those of the parallel studies performed with "conventional" cisplatin. The results show that deactivation of adamplatin(IV) by sulfur-containing compounds (such as glutathione or metallothioneins) is likely to play a less significant role in the mechanism of resistance of tumor cells to adamplatin(IV) in contrast to the role of these reactions in the effects of cisplatin. Moreover, the treatment of tumor cells with adamplatin(IV) does not result in DNA modifications that would be markedly different from those produced by cisplatin. In contrast, the effects of other factors, such as enhanced accumulation of the drug in cells, strong inhibition of DNA polymerization by these adducts, lowered DNA repair, and DNA-protein cross-linking are different from the effects of these factors in the mechanism underlying activity of cisplatin. Hence, the differences between effects of adamplatin(IV) and cisplatin observed in the present work on molecular level may help understand the unique activity of adamplatin(IV).

Address correspondence to: Dr. Viktor Brabec, Institute of Biophysics, Academy of Sciences of the Czech Republic, Kralovopolska 135, CZ-61265 Brno, Czech Republic. E-mail: brabec{at}ibp.cz

eLetters: